Current Cancer Therapy Reviews
Title:Meet the Editor-in-Chief
Volume: 11 Issue: 1
Author(s): Kurt S. Zanker
Affiliation:
Export Options
About this article
Cite this article as:
Zanker S. Kurt, Meet the Editor-in-Chief, Current Cancer Therapy Reviews 2015; 11 (1) . https://dx.doi.org/10.2174/157339471101150706122704
DOI https://dx.doi.org/10.2174/157339471101150706122704 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
TAT-Liposomes: A Novel Intracellular Drug Carrier
Current Protein & Peptide Science In Vivo, Cardiac-Specific Knockdown of a Target Protein, Malic Enzyme- 1, in Rat via Adenoviral Delivery of DNA for Non-Native miRNA
Current Gene Therapy Wet-lab Tested MicroRNA Assays for qPCR Studies with SYBR<sup>®</sup> Green and DNA Primers in Pig Tissues
MicroRNA Cruciferous Plants: Phytochemical Toxicity Versus Cancer Chemoprotection
Mini-Reviews in Medicinal Chemistry The Application of DNA Microarrays to the Study of Cancer
Current Genomics Cyclooxygenase-2 Biology
Current Pharmaceutical Design Hybrid SPECT/CT Imaging in Neurology
Current Radiopharmaceuticals Tobacco, Inflammation, and Respiratory Tract Cancer
Current Pharmaceutical Design Human Apurinic/Apyrimidinic Endonuclease (APE1): An Emerging Anti-Cancer Biomarker
Recent Patents on Biomarkers Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Biomarkers in the Evaluation and Management of Idiopathic Pulmonary Fibrosis
Current Topics in Medicinal Chemistry Role of the Non-Receptor Tyrosine Kinase Fes in Cancer
Current Medicinal Chemistry Inhaled Micro/Nanoparticulate Anticancer Drug Formulations: An Emerging Targeted Drug Delivery Strategy for Lung Cancers
Current Cancer Drug Targets Patent Selections
Recent Patents on DNA & Gene Sequences Multi-Target Mining of Alzheimer Disease Proteome with Hansch’s QSBR-Perturbation Theory and Experimental-Theoretic Study of New Thiophene Isosters of Rasagiline
Current Drug Targets Particulate Systems Based on Poly(Lactic-co-Glycolic)Acid (pLGA) for Immunotherapy of Cancer
Current Pharmaceutical Design Polyamines in the Surface of Lipid Micelles Improve the Cellular Uptake of Antitumoral Agents
Current Biotechnology Computational Models for 5αR Inhibitors for Treatment of Prostate Cancer: Review of Previous Works and Screening of Natural Inhibitors of 5αR2
Current Computer-Aided Drug Design Anti-proliferative Properties of miR-20b and miR-363 from the miR-106a-363 Cluster on Human Carcinoma Cells
MicroRNA Editorial [Hot Topic: Molecular Mechanisms and Therapeutic Reversal of Immune Suppression in Cancer (Guest Editor: Dmitry I. Gabrilovich)]
Current Cancer Drug Targets